Affordable Innovation
With our leading R&D, manufacturing, and registration capabilities, our goal is to bring high-quality, novel treatment options that are both innovative and affordable to patients in need. Here at Hengenix, we put quality first.
Products currently in development include biosimilar and bio-innovative drugs covering a variety of therapeutic areas focusing on oncology and autoimmune diseases.
汉利康® (HLX01): Rituximab injection, the first commercially launched biosimilar in China
汉曲优® (HLX02): Trastuzumab injection, Zercepac® in the EU, first Chinese mAb biosimilar approved in both EU and China
HLX01 RA to obtain NDA approval
HLX10 (PD-1) to enter Phase 3 clinical trials for multiple oncology indications
HLX06 & HLX07 to enter Phase 3 clinical trials
PD-1/PD-L1 to be the backbone
HLX04+HLX10 and HLX07+HLX10 to obtain NDA approval
Learn more about our other locations:
